
## Arend Mosterd

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5700952/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting residual inflammatory risk in coronary disease: to catch aÂmonkey by its tail. Netherlands Heart Journal, 2022, 30, 25-37.	0.3	3
2	Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2. Circulation, 2022, 145, 626-628.	1.6	9
3	Text-mining in electronic healthcare records can be used as efficient tool for screening and data collection in cardiovascular trials: a multicenter validation study. Journal of Clinical Epidemiology, 2021, 132, 97-105.	2.4	23
4	Letter to the editor: Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e71-e71.	1.4	1
5	Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. European Heart Journal, 2021, 42, 2765-2775.	1.0	119
6	Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness. European Journal of Preventive Cardiology, 2021, , .	0.8	3
7	Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy. Atherosclerosis, 2021, 334, 93-100.	0.4	25
8	Colchicine in coronary disease: another renaissance of an ancient drug. Cardiovascular Research, 2021, 117, e4-e6.	1.8	2
9	Sex differences in flow cytometry–based platelet reactivity in stable outpatients suspected of myocardial ischemia. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 879-885.	1.0	11
10	Training general practitioners to improve evidence-based drug treatment of patients with heart failure: aAcluster randomised controlled trial. Netherlands Heart Journal, 2020, 28, 604-612.	0.3	2
11	Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease. Circulation, 2020, 142, 1996-1998.	1.6	81
12	Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein. PLoS ONE, 2020, 15, e0237665.	1.1	29
13	Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine, 2020, 383, 1838-1847.	13.9	1,010
14	Epidemiology of heart failure. European Journal of Heart Failure, 2020, 22, 1342-1356.	2.9	948
15	Time trends in the use and appropriateness of natriuretic peptide testing in primary care: an observational study. BJGP Open, 2020, 4, bjgpopen20X101074.	0.9	3
16	The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. American Heart Journal, 2019, 218, 46-56.	1.2	72
17	Colchicine in Stable Coronary Artery Disease. Clinical Therapeutics, 2019, 41, 30-40.	1.1	23
18	Effectiveness of the European Society of Cardiology/Heart Failure Association website â€~heartfailurematters.org' and an eâ€health adjusted care pathway in patients with stable heart failure: results of the â€~eâ€Vita HF' randomized controlled trial. European Journal of Heart Failure, 2019, 21, 238-246.	2.9	56

AREND MOSTERD

#	Article	IF	CITATIONS
19	Pre-participation screening of asymptomatic athletes. Netherlands Heart Journal, 2018, 26, 123-126.	0.3	15
20	HEART score performance in Asian and Caucasian patients presenting to the emergency department with suspected acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 591-601.	0.4	10
21	Relationship Between Lifelong Exercise Volume and Coronary Atherosclerosis in Athletes. Circulation, 2017, 136, 138-148.	1.6	195
22	Overdiagnosis of heart failure in primary care: a cross-sectional study. British Journal of General Practice, 2016, 66, e587-e592.	0.7	44
23	Suspected acute coronary syndrome in the emergency room: Limited added value of heart type fatty acid binding protein point of care or ELISA tests: The FAME-ER (Fatty Acid binding protein in Myocardial) Tj ETQq1 Care, 2016, 5, 364-374.	1.0,7843 0.4	14 rgBT /Ove
24	Improving usual care after sudden death in the young with focus on inherited cardiac diseases (the) Tj ETQqO 0 0	rgBT /Ove	rlggk 10 Tf 5
25	Rationale, design and baseline results of the Treatment Optimisation in Primary care of Heart failure in the Utrecht region (TOPHU) study: a cluster randomised controlled trial. BMC Family Practice, 2015, 16, 130.	2.9	3
26	COPD in patients with stable heart failure in the primary care setting. International Journal of COPD, 2015, 10, 1219.	0.9	13
27	Unravelling the grey zone: cardiac MRI volume to wall mass ratio to differentiate hypertrophic cardiomyopathy and the athlete's heart. British Journal of Sports Medicine, 2015, 49, 1404-1409.	3.1	15
28	Exercise-related out-of-hospital cardiac arrest in the general population: incidence and prognosis. European Heart Journal, 2013, 34, 3616-3623.	1.0	117
29	Applicability of current diagnostic algorithms in geriatric patients suspected of new, slow onset heart failure. Age and Ageing, 2012, 41, 309-316.	0.7	6
30	Comorbidity Drives Mortality in Newly Diagnosed Heart Failure: A Study Among Geriatric Outpatients. Journal of Cardiac Failure, 2012, 18, 47-52.	0.7	54
31	Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. European Journal of Heart Failure, 2011, 13, 518-527.	2.9	119
32	Preventing sudden cardiac death in athletes: finding the needle in the haystack or closing the barn door?. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 194-196.	3.1	5
33	Age- and gender-specific risk of death after first hospitalization for heart failure. BMC Public Health, 2010, 10, 637.	1.2	35
34	One-year mortality after a first visit to a cardiology outpatient clinic: a useful performance indicator?. Netherlands Heart Journal, 2009, 17, 52-55.	0.3	2
35	Clinical epidemiology of heart failure. Heart, 2007, 93, 1137-1146.	1.2	1,448
36	Clinical implementation of guidelines for cardioverter defibrillator implantation: lost in translation?. Netherlands Heart Journal, 2007, 15, 129-132.	0.3	23

#	Article	IF	CITATIONS
37	Leaflet Fracture of a St. Jude Mechanical Bileaflet Valve. Circulation, 2005, 111, e280-1.	1.6	12
38	The epidemiology of heart failure. European Heart Journal, 1997, 18, 208-225.	1.0	834